A process that aims to make promising new medicines available to patients sooner, and through which patients can access drugs that are not yet licensed for use in the UK. EAMS was started in March 2015 and is run by the Medicines and Healthcare Products Regulatory Agency (MHRA), the government organisation that ensures the safety and effectiveness of all medicines and healthcare devices on the market in the UK.

Share this Post!